Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity.
about
Synthetic glycolipid activators of natural killer T cells as immunotherapeutic agentsFine tuning a well-oiled machine: Influence of NK1.1 and NKG2D on NKT cell development and functionNKT cell networks in the regulation of tumor immunityInduced pluripotent stem cell (iPSCs) and their application in immunotherapyThe immunoregulatory role of type I and type II NKT cells in cancer and other diseasesMechanisms for Glycolipid Antigen-Driven Cytokine Polarization by V 14i NKT CellsGlycolipids that Elicit IFN-γ-Biased Responses from Natural Killer T CellsNew ways to turn on NKT cellsAlpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine.Innate invariant NKT cells recognize Mycobacterium tuberculosis-infected macrophages, produce interferon-gamma, and kill intracellular bacteria.Invariant natural killer T-cell control of type 1 diabetes: a dendritic cell genetic decision of a silver bullet or Russian roulette.Fatty acid amide hydrolase shapes NKT cell responses by influencing the serum transport of lipid antigen in mice.Application of nanotechnologies for improved immune response against infectious diseases in the developing worldDistinct and overlapping effector functions of expanded human CD4+, CD8α+ and CD4-CD8α- invariant natural killer T cellsCD1d-based combination therapy eradicates established tumors in mice.CD1d activation and blockade: a new antitumor strategyCirculating myeloid dendritic cells of advanced cancer patients result in reduced activation and a biased cytokine profile in invariant NKT cells.Induced pluripotency as a potential path towards iNKT cell-mediated cancer immunotherapy.Invariant natural killer T cells regulate anti-tumor immunity by controlling the population of dendritic cells in tumor and draining lymph nodes.Identification of an important immunological difference between virulent varicella-zoster virus and its avirulent vaccine: viral disruption of dendritic cell instructionSevere functional impairment and elevated PD-1 expression in CD1d-restricted NKT cells retained during chronic HIV-1 infectionPreclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma modelDeveloping understanding of the roles of CD1d-restricted T cell subsets in cancer: reversing tumor-induced defects.Airborne lipid antigens mobilize resident intravascular NKT cells to induce allergic airway inflammation.Transfer of mRNA Encoding Invariant NKT Cell Receptors Imparts Glycolipid Specific Responses to T Cells and γδT CellsDifferential contribution of dendritic cell CD1d to NKT cell-enhanced humoral immunity and CD8+ T cell activation.SAP expression in invariant NKT cells is required for cognate help to support B-cell responsesScavenger receptors target glycolipids for natural killer T cell activation.Differential effects of age on circulating and splenic leukocyte populations in C57BL/6 and BALB/c male mice.Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma.Natural Killer Dendritic Cells Enhance Immune Responses Elicited by α -Galactosylceramide-Stimulated Natural Killer T Cells.Cutting edge: CD1d restriction and Th1/Th2/Th17 cytokine secretion by human Vδ3 T cells.Cross-regulation between distinct natural killer T cell subsets influences immune response to self and foreign antigens.Glycolipid ligands of invariant natural killer T cells as vaccine adjuvantsIdentification of antigen-presenting dendritic cells in mouse aorta and cardiac valves.Harnessing human CD1d restricted T cells for tumor immunity: progress and challenges.The specialized iNKT cell system recognizes glycolipid antigens and bridges the innate and acquired immune systems with potential applications for cancer therapy.Invariant natural killer T cell-based immunotherapy for cancer.Harnessing natural killer T (NKT) cells in human myeloma: progress and challenges.Targeting skin dendritic cells to improve intradermal vaccination.
P2860
Q26748456-36FFD38B-686F-4730-BEF6-F0A1009CC78AQ26830239-3511C87A-C690-4701-9BB2-A126834F384FQ26866223-1D94636E-DAA8-48C9-ABF2-48A3723C810DQ26996540-9F3BEF71-D731-4B76-8965-26966304A486Q27027556-89B97F88-274B-414A-837D-2B0DF7B67024Q27658388-AAD5AED2-7816-4EBF-B4FA-AC5E2BAA95C3Q27676395-508C9DD1-FD69-40AB-9E0A-7258AE126843Q27693911-320B5700-5A3F-4310-B478-422BDF62CA81Q30377447-3227D981-ACE8-4858-AE9E-B4226BAD14BCQ33392693-6AA8E645-53FF-4CC3-A365-7F7FCD1BB622Q33604484-E07B4661-60F7-41E9-94A3-5D2C3A883E75Q33882880-C521CF52-09B4-4A7A-90B5-E9E3F0206CD0Q33894321-1F5EEAD6-FE70-4E7F-9240-B4B1A6D4683CQ34103244-DBFD9EA4-22A8-42DE-A80A-FFAE7C88D7D7Q34257887-2B710641-3B05-4C88-A8B7-EA09F079F232Q34257902-E2360FB1-8E54-4407-A7B1-A2260C04F6B5Q34257926-3BE80837-0DE1-48FC-9C16-8C77FA731A77Q34275397-19E8A464-1A87-4C72-A6B1-DD945D75F321Q34389948-64E3B122-FDF0-4E6B-A0BF-A82A73CB53B7Q34549746-94C9F66C-95C4-4089-B213-212B6CC5E6B5Q34604276-E38FEDA5-EBB9-4570-9CDD-7153A98423DAQ34761156-5A25D4D8-CEF4-41D3-85C1-757E03025641Q35127172-D5B249D3-6A22-42AD-81FF-74CA7E60C8EDQ35237482-847E11F3-A7E5-49C8-8D1C-CBF30B28C050Q35677421-CDFD7FBA-E35D-4B0C-B25F-45A0118FD565Q35912977-17D20C6C-A53A-4F5E-8673-696201D70E55Q36079768-18A1146F-3214-486B-ABB2-D976D6DC597FQ36357825-FBA75C3A-252E-42F2-B756-E08F18923134Q36499541-F304D7B4-7013-43AF-902B-10890D1CE16AQ36542800-01659510-FC12-4793-B0A3-665086F35CD1Q37002737-76C860BD-B38A-4BAA-920C-E5984F30EBB3Q37039445-D720AED0-BE02-4577-B08A-A4C28D5FA23DQ37121488-EC07A08E-ADB5-4AB8-A3E3-ACFEFD041855Q37187603-75C9EB02-20A7-4DB1-BA1D-0E01B7F1C98AQ37234314-2D1AF067-EDB4-4D9E-9551-8AE25EE61A00Q37388427-C06D6FC0-220C-4715-B08D-E70551DFAF01Q37621786-A5D3FFF4-F55C-4613-AC2B-FE07F73AB283Q37773278-AAFD0195-A58E-49E0-A284-5AD7B5B55850Q37828297-A8DB457A-D593-447A-85EE-FCFF70C2B0D8Q37831193-D83AD1DE-6372-4B9A-A09F-AD52B3076FD5
P2860
Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Innate Valpha14(+) natural kil ...... g to strong adaptive immunity.
@en
type
label
Innate Valpha14(+) natural kil ...... g to strong adaptive immunity.
@en
prefLabel
Innate Valpha14(+) natural kil ...... g to strong adaptive immunity.
@en
P2093
P2860
P1476
Innate Valpha14(+) natural kil ...... g to strong adaptive immunity.
@en
P2093
Hiroaki Hemmi
Kanako Shimizu
Ralph M Steinman
Shin-Ichiro Fujii
P2860
P304
P356
10.1111/J.1600-065X.2007.00561.X
P577
2007-12-01T00:00:00Z